Compare STMicroelectronics NV (STM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
STMicroelectronics NV vs State Street SPDR S&P Biotech ETF — how do they compare? STMicroelectronics NV trades at $55.09 (market cap $49.21B), while State Street SPDR S&P Biotech ETF trades at $159.65. The key difference: STMicroelectronics NV pays a 0.65% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, STMicroelectronics NV nearer its low. Which is the better fit depends on your goals.
| STM | XBI | |
|---|---|---|
Market Cap | $49.21B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $79.91 | $164.28 |
52-Week Low | $21.20 | $86.92 |
Enterprise Value | $47.21B | — |
Dividend Yield | 0.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
STM's stock trades at $55.09, up 1.36% on the day, with a neutral technical signal and bearish moving average trend. The company reported Q2 2026 EPS of $0.31, beating expectations, but faces profitability challenges with a net margin of 3.56%. Recent news highlights strong AI data center growth potential, targeting over $2 billion in revenues by 2027. Cash flow improved in 2025 with net cash flow of $555 million.
The outlook is mixed; analyst consensus is bullish with a $74.63 price target, but high P/E of 107.92 indicates premium valuation. Key opportunities include AI and auto demand, while risks involve margin pressure and competitive threats. Execution on growth targets is critical for upside.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
